DSDalila Sellami

Dalila Sellami

*This is an algorithmically generated author record based on publicly available information.

Dalila Sellami has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

    by D. Sellami, B. Dharan, C. Wilke, S.J. Scherer, S. Hirawat

    Tumor heterogeneity is a major challenge for drug development, and changes in heterogeneity are thought to contribute to anticancer treatment resistance. However, the standard diagnostic approach in clinical trials relies on analysis of a single (usually archival) sample from the primary tumor [1]. This provides limited characterization of a single tumor at initial diagnosis that is not necessarily representative of current disease status [1]. Recent studies have also highlighted challenges with intratumoral heterogeneity in advanced cancers [2, 3]. The success of targeted therapies is closely associated with identification of the target within a tumor sample. However, most tumors develop resistance due to intratumoral heterogeneity, clonal evolution, and selection pressure [1–4].


  • Exposure‐Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors

    by Jocelyn Zhou, Michelle Quinlan, Eunju Hurh, Dalila Sellami

    Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway-dependent tumors, and has recently been approved in the indication of locally advanced basal cell carcinoma. A comprehensive exposure-response analysis was conducted to further characterize the relationship of sonidegib exposure to efficacy and safety. Minimum observed plasma concentration at pre-dose (Cmin), peak concentration (Cmax), and area under the curve were used as exposure endpoints. Exposure-efficacy analyses included data from 190 patients who received sonidegib 200 mg or 800 mg once daily in the primary efficacy study. Objective response rate (ORR) (complete response [CR] or partial response [PR]), progression-free survival (PFS), and time to tumor response (TTR) were assessed by logistic regression, Cox regression and Kaplan-Meier analyses. Exposure-safety (creatine phosphokinase [CK] elevation) analyses included data from 336 patients pooled from four clinical trials and included doses across ranges of 100–3000 mg once daily and 250–750 mg twice daily. Similar plasma exposure was observed between responders and non-responders. The logistic regression model of Week 5 Cmin vs. ORR indicated no relationship between sonidegib exposure resulting from 200 mg or 800 mg doses and the probability of CR or PR. A similar conclusion of no exposure-efficacy relationship was drawn from the PFS and TTR analyses. Increased exposure was associated with a greater risk of Grade 3 or 4 CK elevation, with lower risk in females than in males when using Cmin in the model. These analyses support the sonidegib dose recommendation for registration and are consistent with clinical observations. This article is protected by copyright. All rights reserved


  • Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors

    by Michelle Quinlan, Jocelyn Zhou, Eunju Hurh, Dalila Sellami

    Sonidegib prevents activation of the Hedgehog signal transduction pathway. This PK-QT analysis has been performed to test for potential prolongation of the QT/QTc interval during extended use, and to understand the exposure-QT relationship for sonidegib in patients and in healthy volunteers (HV). A pooled analysis of the change in QT interval corrected for heart rate according to Fridericia’s formula was conducted across four patient studies from a total of 341 patients (n = 211, 102, 21, and 7 from the phase II pivotal study A2201, study X2101, study X1101, and study B2209, respectively), and across four healthy volunteer studies from a total of 204 healthy volunteers (n = 146, 36, 16, and 6 from study A2114, study A1102, study A2108, and study A2110, respectively). A PK/ECG subgroup of 62 patients from the pivotal study A2201 was also analyzed to assess the QT prolongation risk at steady-state exposures. Sonidigib PK and ECG data were matched to determine the change from baseline in QTcF using a linear mixed-effect model. Clinical data indicate sonidegib does not cause QTc prolongation. ΔQTcF at steady-state concentrations for both 200 and 800-mg doses were all below 5 ms. The highest mean ΔQTcF at steady state was −3.9 ms at week 17 pre-dose in the sonidegib 200-mg group and 2.7 ms at 2-h post-dose in the sonidegib 800-mg group. The upper one-sided 95 % confidence interval of the estimated ΔQTcF at steady-state concentrations from the linear mixed-effect models were all <10 ms. No cases of ventricular arrhythmia or torsades de pointes and no deaths associated with QT prolongation have been reported in the sonidegib clinical development program. Based on these analyses, there is no evidence of QT prolongation associated with sonidegib 200 or 800 mg in solid tumor patients and HV.


  • Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

    by Varun Goel, Eunju Hurh, Andrew Stein, Jerry Nedelman, Jocelyn Zhou, Ovidiu Chiparus, Pai-Hsi Huang, Sven Gogov, Dalila Sellami

    Purpose Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate effects. Methods PK data from five phase 1 or 2 studies (N = 436) in the dose range from 100 to 3000 mg were analyzed using NONMEM. A two-compartment base model with first-order absorption, lag time, linear elimination, and bioavailability that decreased with dose was updated to describe the PK of sonidegib. Covariate analyses were performed and were incorporated into the population PK full model. Results The base and full models were robust with a good fit to the study data. Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %). Clinically relevant covariate effects were: A high-fat meal increased sonidegib bioavailability fivefold, healthy volunteers had threefold higher clearance, sonidegib bioavailability decreased with increasing dose levels, and PPI coadministration reduced sonidegib bioavailability by 30 %. Sonidegib PK was not significantly impacted by baseline age, weight, total bilirubin, alanine aminotransferase, albumin, creatinine clearance, gender, and ethnicity (Western countries versus Japanese). Conclusion No dose adjustment is needed for mild hepatic impairment, mild and moderate renal impairment, age, weight, gender, or ethnicity. This population PK model adequately characterizes sonidegib PK characteristics and can be used for various simulations and applications.


  • A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.

    by Teresa Macarulla, Josep Tabernero, Daniel H. Palmer, Sunil Sharma, Kenneth H. Yu, Dalila B. Sellami, Jocelyn Zhou, Wu Yi, Hildegard Boss, Eunice L Kwak

    371 Background: Sonidegib (LDE225) is a potent, selective, and orally bioavailable inhibitor of smoothened receptor that demonstrated preclinical activity in combination with gemcitabine (GEM). Here, we present data from a phase 1b trial of sonidegib in combination with GEM in patients (pts) with pancreatic adenocarcinoma (PA). Methods: Pts with histologically or cytologically confirmed, locally advanced, or metastatic PA who had not been treated previously or had progressed despite prior chemotherapy (other than GEM) were included in the study. Dose escalation started with sonidegib 400 mg, once a day, in combination with GEM 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle. Results: A total of 18 pts were enrolled (9 pts each the in dose escalation and dose expansion phases). Pts discontinued the study because of disease progression (n = 11, 61.1%), consent withdrawal (n = 3, 16.7%), administrative problems (n = 3, 16.7%), and grade 3 or 4 blood creatine kinase (CK) elevation (n = 1, 5.6%). Three of 9 pts in dose escalation phase experienced dose-limiting toxicities during the first 8 weeks including grade 3 mucositis (n = 1), grade 3 CK elevation (n = 1), and grade 3 aspartate aminotransferase elevation (n = 1). Drug-related adverse events (AEs) of all grades were reported in 14 pts (77.8%) and grade 3 or 4 AEs were reported in 10 pts (55.6%). The most commonly reported AEs were anemia and nausea. No pharmacokinetic (PK) interaction was observed. Based on considerations of the statistical model, clinical assessment of safety, tolerability, PK, and pharmacodynamic results, maximum-tolerated dose and recommended dose were established as 400 mg of sonidegib in combination with the fixed standard dose of GEM (1000 mg/m2).The objective response rate was 11.1% and the median progression-free survival (PFS) was 4.9 months. Conclusions: The combination of sonidegib and GEM was generally well tolerated with moderate activity. Although no formal comparison can be made due to small sample size of this study, this combination provided a median PFS comparable to the current standard of care without conferring any additional clinical benefit. Clinical trial information: NCT01487785.


  • Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)

    by Michael Robert Migden, Alexander David Guminski, Ralf Gutzmer, Luc Yves Dirix, Karl D. Lewis, Patrick Combemale, Robert Herd, Sven Gogov, Tingting Yi, Manisha Mone, et al.

    9009a^ Background: Pts with advanced BCC have limited treatment options. Sonidegib blocks the hedgehog pathway (overexpressed in ≥ 95% of BCCs) by selective inhibition of smoothened. Methods: In this ph 2 study (BOLT; NCT01327053), pts with LaBCC, not amenable to curative surgery or radiation, or mBCC were randomized 1:2 to receive sonidegib 200 or 800 mg daily. The primary endpoint, objective response rate (ORR—histopathologically confirmed complete response [CR] + partial response [PR]—achieved if point estimate ≥ 30% and 95% CI lower bound > 20% [either arm]), and secondary endpoints duration of response (DoR), CR rate, time to tumor response (TTR), and PFS were assessed according to modified RECIST (mRECIST; LaBCC) or RECIST 1.1 (mBCC) by central review. Statistical comparison of arms was not planned. Safety was assessed up to ≈30 days post-last dose. Results: Pts (194 LaBCC; 36 mBCC) were enrolled from Jul 2011-Jan 2013. The primary endpoint was met for both arms (Table; median follow-up 13.9 mo). Median exposure was 8.9 (200 mg) and 6.5 mo (800 mg). AEs were less frequent at 200 mg. AEs leading to discontinuation (200/800 mg) included muscle spasms (3.8%/8.7%), dysgeusia (2.5%/4.7%), weight decreased (2.5%/4.7%), and nausea (2.5%/4.0%). Conclusions: Meaningfuldisease control with sustained DoR and prolonged PFS were achieved with both doses of sonidegib, with a more favorable benefit-risk profile for 200 mg. Clinical trial information: NCT01327053.


  • Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

    by Alain Ravaud, Shweta R. Urva, Kai Grosch, Wing K. Cheung, Oezlem Anak, Dalila B. Sellami